Business / Finance

RSS

Essilor first quarter consolidated revenue increases 21% to €1,269.9M

Essilor International, the world leader in ophthalmic optics, today announced that consolidated revenue for the three months ended March 31, 2012 totaled €1,269.9 million, an increase of 21%, excluding the currency effect, over the year-earlier period.

24 Apr 2012

Health Management first quarter net revenue increases 18.4% to $1.485B

Health Management Associates, Inc. today announced its consolidated financial results for the first quarter ended March 31, 2012.

24 Apr 2012

Nephros granted rights to market products based on Medica's Medisulfone ultrafiltration technology

Nephros, Inc., a medical device company developing and marketing filtration products for therapeutic applications, infection control, and advanced water purification solutions, today announced that the company has entered into a strategic license and supply agreement with Medica S.p.A.

23 Apr 2012

Dehaier to distribute Timesco's laryngoscope Optima series of products in mainland China

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it has signed a strategic cooperation agreement with Timesco of London Ltd., one of the most progressive surgical and medical companies in the U.K.

23 Apr 2012

Aggredyne closes $3 million Series A convertible preferred stock financing

Aggredyne, Inc., a Houston-based biomedical diagnostics company that is defining a new standard for platelet function testing, sold out and closed a $3 million Series A convertible preferred stock financing.

23 Apr 2012

Oligomerix to advance tau protease inhibitor program with $2M Series A financing

Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease and related neurodegenerative disorders, announced today the completion of approximately $2 million in Series A financing, which includes both issuance of new convertible preferred shares and debt conversion.

23 Apr 2012

Healthways announces acquisition of Ascentia Health Care Solutions

Ben R. Leedle, Jr., president and chief executive officer of Healthways, announced that the Company has acquired Ascentia Health Care Solutions, a Philadelphia area based company whose business is designed to support and promote population health management, patient centered programs, payer strategies and physician practice enhancement programs.

23 Apr 2012

IntegenX to accelerate commercialization of human DNA identification system with SV acquisition

IntegenX Inc., a privately held company that is a leader in the emerging field of rapid human DNA identification, today announced that it has acquired SV Corp, a wholly owned subsidiary of GE Healthcare Bio-Sciences. IntegenX will leverage SV Corp's products and intellectual property assets to expand its consumables offering and to accelerate the commercialization of its RapidHIT 200 Human DNA Identification System.

23 Apr 2012

Champ Medics to market ETView's VivaSight airway management platform in Taiwan

ETView Medical, Ltd. announced today that it has entered into a distribution agreement with Champ Medics Co., Ltd..

23 Apr 2012

Delcath closes $20M credit facility

Delcath Systems, Inc. today announced it has closed a $20 million working capital line of credit revolver with Silicon Valley Bank, a leading provider of banking services in the life sciences. The credit facility is available for general corporate purposes supporting the overall growth and development of the Company.

23 Apr 2012

Pfizer enters agreement to divest Nutrition business to Nestlé for $11.85B

Pfizer today announced that it has entered into an agreement to divest its Nutrition business to Nestlé for $11.85 billion in cash. Pfizer's Nutrition business recorded revenues of approximately $2.1 billion in 2011, an increase of 15% versus 2010.

23 Apr 2012

CTI first quarter net loss decreases 66% to $17.4 million

Cell Therapeutics, Inc. today reported financial results and recent accomplishments for the first quarter of 2012.

21 Apr 2012

PhotoVoltaic Solar Cells announces name change to MetaStat

MetaStat, Inc., a life science company focused on developing and commercializing proprietary clinical diagnostic tests that predict the probability of cancer metastasis, as well as companion therapeutics to prevent systemic metastasis, today announced that it has changed its name from PhotoVoltaic Solar Cells, Inc. to MetaStat, Inc. effective April 9, 2012.

21 Apr 2012

LifeMap Sciences, BioTime to acquire XenneX

BioTime, Inc. and its wholly owned subsidiary LifeMap Sciences today announced that they have signed a definitive agreement to acquire XenneX, Inc. through a merger of XenneX into LifeMap Sciences. The acquisition is expected to close within thirty days.

21 Apr 2012

Standard Register first quarter total revenues decline 4% to $157.6M

Standard Register today announced its financial results for the first quarter 2012. The Company reported revenue of $157.6 million and a net loss of $5.1 million, or $0.18 per share. The results compare to prior year revenue of $164.9 million and net income of $0.4 million, or $0.01 per diluted share.

21 Apr 2012

UnitedHealth Group's consolidated first quarter revenues increase 7% to $27.3B

UnitedHealth Group today reported first quarter results, highlighted by strong enrollment and revenue growth in each of UnitedHealthcare's benefits businesses and well-diversified revenue growth at Optum. First quarter 2012 net earnings were $1.31 per share, with continued performance on key financial and operational measures.

19 Apr 2012

Intervertebral disc repair phase 2 trial update from Mesoblast

Global regenerative medicine company Mesoblast Limited (ASX:MSB) has announced that its Phase 2 clinical trial investigating the use of allogeneic, or off-the-shelf, Mesenchymal Precursor Cells (MPCs) for non-surgical restoration of degenerated intervertebral discs and treatment of low back pain has enrolled 50% of the total study patients. This rapid rate of enrolment attests to the major unmet medical need and to the relative simplicity of Mesoblast’s non-surgical procedure. Mesoblast expects to complete full enrolment by early third quarter.

17 Apr 2012